Revolutionizing Melanoma Staging with Advanced CEUS

Preoperative staging of cutaneous melanoma requires precise identification of the sentinel lymph node. Consequently, clinicians constantly seek safer and more accurate localization techniques. Recently, a prospective study evaluated Sonazoid-enhanced ultrasound as a non-radioactive alternative. In addition, this approach safely maps lymphatic drainage and assesses nodal characteristics. Furthermore, this method demonstrates high diagnostic accuracy, which can significantly streamline clinical workflows.

The Role of Sonazoid-Enhanced Ultrasound in Nodal Mapping

In this clinical trial, researchers enrolled 71 subjects with stage Ib-II melanoma. Specifically, the participants received perilesional intradermal microbubble injections alongside standard lymphoscintigraphy. Subsequently, surgeons performed sentinel lymph node biopsies to verify the imaging results. Interestingly, the microbubble-based method achieved an impressive 97.3% success rate in identifying sentinel nodes. Moreover, the technique detected an average of 2.1 nodes per patient, showcasing its high sensitivity. Therefore, this non-invasive modality could successfully complement traditional radioactive mapping methods.

Diagnostic Accuracy and Clinical Relevance

Beyond localization, the novel technique provides valuable diagnostic information regarding metastatic involvement. For instance, the diagnostic analysis revealed 82.1% sensitivity, 88.4% specificity, and 85.9% accuracy. Additionally, specific primary tumor features like ulceration, high mitotic count, and HMB45 positivity strongly correlated with metastasis. Importantly, clinicians reported zero contrast-related adverse events during the study. Thus, the procedure appears both highly effective and exceptionally safe for clinical use. Ultimately, incorporating this technique into standard workflows can optimize surgical planning for melanoma patients.

Frequently Asked Questions

Q1: What is Sonazoid and how does it assist in melanoma staging?

Sonazoid is a perfluorobutane microbubble contrast agent. During staging, clinicians inject it intradermally to map lymphatic pathways and identify sentinel lymph nodes in real time.

Q2: Is Sonazoid-enhanced ultrasound safe for patients?

Yes, this technique is safe. Indeed, researchers observed zero contrast-related adverse events during the entire prospective clinical study.

Q3: How does the diagnostic accuracy of this method compare to histopathology?

The ultrasound technique demonstrates high accuracy. Specifically, it achieved 82.1% sensitivity, 88.4% specificity, and 85.9% overall diagnostic accuracy for detecting metastasis.

References

1. Jiang B et al. Sonazoid-enhanced ultrasound for preoperative localization and characterization of sentinel lymph nodes in patients with cutaneous melanoma. Eur Radiol. 2026 May 25. doi: 10.1007/s00330-026-12640-2. PMID: 42185612.
2. Goldberg BB et al. Contrast-enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of Sonazoid in a melanoma tumor animal model. J Ultrasound Med. 2011;30(4):441-453. doi:10.7863/jum.2011.30.4.441.
3. Cui XW et al. Contrast enhanced ultrasound of sentinel lymph nodes. J Ultrason. 2013;13(52):73-81. doi:10.15557/JoU.2013.0006.